scispace - formally typeset
Search or ask a question
Institution

Laval University

EducationQuébec, Quebec, Canada
About: Laval University is a education organization based out in Québec, Quebec, Canada. It is known for research contribution in the topics: Population & Context (language use). The organization has 31177 authors who have published 69549 publications receiving 2435031 citations.


Papers
More filters
Journal ArticleDOI
17 Apr 2019-Joule
TL;DR: In this paper, a ladder-type electron-deficient core-based central fused ring (Dithienothiophen[3.2-b]- pyrrolobenzothiadiazole) with a benzothiadiadiazoles (BT) core was proposed to fine-tune its absorption and electron affinity.

3,513 citations

Journal ArticleDOI
29 Oct 1993-Science
TL;DR: Analysis of cortical and thalamic networks at many levels, from molecules to single neurons to large neuronal assemblies, with a variety of techniques, is beginning to yield insights into the mechanisms of the generation, modulation, and function of brain oscillations.
Abstract: Sleep is characterized by synchronized events in billions of synaptically coupled neurons in thalamocortical systems. The activation of a series of neuromodulatory transmitter systems during awakening blocks low-frequency oscillations, induces fast rhythms, and allows the brain to recover full responsiveness. Analysis of cortical and thalamic networks at many levels, from molecules to single neurons to large neuronal assemblies, with a variety of techniques, ranging from intracellular recordings in vivo and in vitro to computer simulations, is beginning to yield insights into the mechanisms of the generation, modulation, and function of brain oscillations.

3,382 citations

Journal ArticleDOI
TL;DR: Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema and a increased risk of hypotensive symptoms.
Abstract: Background In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes. Methods After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy). The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. Results Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg greater reduction) and the combination-therapy group (a 2.4/1.4 mm Hg greater reduction) than in the ramipril group. At a median follow-up of 56 months, the primary outcome had occurred in 1412 patients in the ramipril group (16.5%), as compared with 1423 patients in the telmisartan group (16.7%; relative risk, 1.01; 95% confidence interval [CI], 0.94 to 1.09). As compared with the ramipril group, the telmisartan group had lower rates of cough (1.1% vs. 4.2%, P<0.001) and angioedema (0.1% vs. 0.3%, P = 0.01) and a higher rate of hypotensive symptoms (2.6% vs. 1.7%, P<0.001); the rate of syncope was the same in the two groups (0.2%). In the combination-therapy group, the primary outcome occurred in 1386 patients (16.3%; relative risk, 0.99; 95% CI, 0.92 to 1.07); as compared with the ramipril group, there was an increased risk of hypotensive symptoms (4.8% vs. 1.7%, P<0.001), syncope (0.3% vs. 0.2%, P = 0.03), and renal dysfunction (13.5% vs. 10.2%, P<0.001). Conclusions Telmisartan was equivalent to ramipril in patients with vascular disease or highrisk diabetes and was associated with less angioedema. The combination of the two drugs was associated with more adverse events without an increase in benefit. (ClinicalTrials.gov number, NCT00153101.)

3,262 citations

Journal ArticleDOI
Evelina Tacconelli1, Elena Carrara1, Alessia Savoldi1, Stéphan Juergen Harbarth2, Marc Mendelson3, Dominique L Monnet4, Céline Pulcini, Gunnar Kahlmeter, Jan Kluytmans5, Yehuda Carmeli6, Marc Ouellette7, Kevin Outterson8, Jean B. Patel9, Marco Cavaleri10, Edward Cox11, Christopher R. Houchens12, M Lindsay Grayson13, Paul Hansen14, Nalini Singh15, Ursula Theuretzbacher, Nicola Magrini2, Aaron O. Aboderin, Seif Al-Abri, Nordiah Awang Jalil, Nur Benzonana, Sanjay Bhattacharya, Adrian Brink, Francesco Robert Burkert, Otto Cars, Giuseppe Cornaglia, Oliver J. Dyar, Alexander W. Friedrich, Ana Cristina Gales, Sumanth Gandra, Christian G. Giske, Debra A. Goff, Herman Goossens, Thomas Gottlieb, Manuel Guzman Blanco, Waleria Hryniewicz, Deepthi Kattula, Timothy Jinks, Souha S. Kanj, Lawrence Kerr, Marie-Paule Kieny, Yang Soo Kim, Roman S. Kozlov, Jaime Labarca, Ramanan Laxminarayan, Karin Leder, Leonard Leibovici, Gabriel Levy-Hara, Jasper Littman, Surbhi Malhotra-Kumar, Vikas Manchanda, Lorenzo Moja, Babacar Ndoye, Angelo Pan, David L. Paterson, Mical Paul, Haibo Qiu, Pilar Ramon-Pardo, Jesús Rodríguez-Baño, Maurizio Sanguinetti, Sharmila Sengupta, Mike Sharland, Massinissa Si-Mehand, Lynn L. Silver, Wonkeung Song, Martin Steinbakk, Jens Thomsen, Guy E. Thwaites, Jos W. M. van der Meer, Nguyen Van Kinh, Silvio Vega, Maria Virginia Villegas, Agnes Wechsler-Fördös, Heiman F. L. Wertheim, Evelyn Wesangula, Neil Woodford, Fidan O Yilmaz, Anna Zorzet 
TL;DR: Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria, and include antibiotic-resistant bacteria responsible for community-acquired infections.
Abstract: Summary Background The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs. Methods We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated. The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria. Findings We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline. We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff. Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa , and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae. The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus . Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori , and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae , and Salmonella typhi were included in the high-priority tier. Interpretation Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria. The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae , and H pylori . Funding World Health Organization.

3,184 citations

Journal ArticleDOI
14 Mar 1996-Nature
TL;DR: The last version of the Généthon human linkage map is reported, which consists of 5,264 short tandem repeat polymorphisms with a mean heterozygosity of 70%.
Abstract: The great increase in successful linkage studies in a number of higher eukaryotes during recent years has essentially resulted from major improvements in reference genetic linkage maps, which at present consist of short tandem repeat polymorphisms of simple sequences or microsatellites. We report here the last version of the Genethon human linkage map. This map consists of 5,264 short tandem (AC/TG)n repeat polymorphisms with a mean heterozygosity of 70%. The map spans a sex-averaged genetic distance of 3,699 cM and comprises 2,335 positions, of which 2,032 could be ordered with an odds ratio of at least 1,000:1 against alternative orders. The average interval size is 1.6 cM; 59% of the map is covered by intervals of 2 cM at most and 1% remains in intervals above 10 cM.

2,982 citations


Authors

Showing all 31642 results

NameH-indexPapersCitations
Luigi Ferrucci1931601181199
Marc G. Caron17367499802
Douglas F. Easton165844113809
Vilmundur Gudnason159837123802
Grant W. Montgomery157926108118
Johan G. Eriksson1561257123325
Terrence J. Sejnowski155845117382
Claude Bouchard1531076115307
Peter B. Jones145185794641
Robert C. Gallo14582568212
Graham G. Giles136124980038
Jean-Pierre Després13473690118
Gilbert Laporte12873062608
Mika Juvela12753389809
Vincenzo Di Marzo12665960240
Network Information
Related Institutions (5)
University of British Columbia
209.6K papers, 9.2M citations

96% related

University of Toronto
294.9K papers, 13.5M citations

95% related

University of California, Davis
180K papers, 8M citations

92% related

University of Minnesota
257.9K papers, 11.9M citations

92% related

University of Florida
200K papers, 7.1M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023144
2022692
20214,077
20203,933
20193,558
20183,287